Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2007 December;53(4) > Minerva Gastroenterologica e Dietologica 2007 December;53(4):337-50

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Gastroenterologica e Dietologica 2007 December;53(4):337-50

language: English

Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?

Ciesek S., Manns M. P., Wedemeyer H.

Department of Gastroenterology Hepatology and Endocrinology Hannover Medical School Hannover, Germany


PDF  


Treatment of hepatitis C after liver transplantation can be challenging as graft rejection and graft hepatitis caused by hepatitis C virus (HCV) may be difficult to distinguish. Immunosup-pressive medications may significantly alter the course of hepatitis C in liver transplant recipients. Moreover, single substances have been shown to display antiviral effects in vitro while others are believed to have antifibrotic properties. This review summarizes the modes of action of different classes of immunosuppressive drugs used after liver transplantation and discusses pros and cons of individual drugs in the setting of HCV infection. No definite recommendation for an optimal immunosuppressive regimen can be given at this stage. The most important lesson learned during the last two decades is that acute rejection episodes have to be avoided in particular in hepatitis C since these are associated with reduced graft and patient survival. Further trials are urgently needed to clarify the role of different immunosuppressive compounds in hepatitis C after transplantation.

top of page

Publication History

Cite this article as

Corresponding author e-mail